Entropy Neurodynamics (ASX:ENP) completed dosing of the first patient with the second infusion of its TRP-8803 drug candidate, or intravenous-infused psilocin, in its binge eating disorder trial being conducted alongside Swinburne University, according to a Tuesday Australian bourse filing.

The planned clinical trial, which aims to recruit a total of 12 patients suffering from binge eating disorder, in two six-person groups, the company said. Each group will be given two doses of TRP-8803 14 days apart, along with supportive psychotherapy.

The patient will undergo supportive psychotherapy, ahead of post-treatment review in four weeks, the company said.